Chemicals

1,3,5-Tris(3,3,3-trifluoropropyl)methylcyclotrisiloxane

We are 1,3,5-Tris(3,3,3-trifluoropropyl)methylcyclotrisiloxane CAS:2374-14-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1,3,5-Tris(3,3,3-trifluoropropyl)methylcyclotrisiloxane

CAS.NO:2374-14-3

Synonyms:1,3,5-Tris(3,3,3-trifluoropropyl)-1,3,5-trimethylcyclotrisiloxane; Fluorosilicone cyclic trimer; Tristrifluoropropylmethylcyclotrisiloxane;

1,3,5-Tris[(3,3,3-trifluoropropyl)methyl]cyclotrisiloxane;

Molecular Formula:C12H21F9O3Si3

Molecular Weight:468.53500

Physical and Chemical Properties:

Density:1.24;

Melting point:35oC;

Boiling point:95oC;

Flash point:90oC;

Index of Refraction:1.38;

Specification:

Appearance:Translucent to white waxy solid

Purity(GC):≥99.0%

Packing:25 kg/drum, can also be packaged according to customer requirements

Storage:Store in a cool, ventilated place

Application:It is used for manufacturing of fluorosilicone rubber (fluorinated silicone rubber, FSR), fluorosilicone fluid(fluorinated silicone fluid).

1,3,5-Tris(3,3,3-trifluoropropyl)methylcyclotrisiloxane

Related News: The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.3-BAP2NA-B CAS:944801-33-6 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.rac-1-(4-Fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile CAS:64169-67-1 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.42518-98-9 ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.

Product Name
1,2,3,4-Tetrahydro-benzo[b]azepin-5-one	View Details
5-pyrrol-1-yl-1,3-dihydrobenzimidazole-2-thione Cas:172152-53-3	View Details
4-cyclopropylnaphthalen-1-amine Hydrochloride Cas:1533519-92-4	View Details